N/A
N=40
Bupropion in the Treatment of Methamphetamine Dependence
Methamphetamine Use Disorder
Bottom Line
View on ClinicalTrials.gov: NCT00572234 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcome: Primary: Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. — 5.6; 6.0 days
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- bupropion SR (Drug)
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- All
- Sponsor
- University of Nebraska
- Primary completion
- Apr 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. |
5.6; 6.0 | — |
Summary
Methamphetamine dependence is a significant drug use disorder in the Midwest. While a number of psychosocial and pharmacological treatments have been studied, no specific treatments for methamphetamine have been identified. This study is a collaborative pre-clinical and clinical partnership examining bupropion in the treatment of methamphetamine dependence.
Eligibility Criteria
Inclusion Criteria
- patient in the substance use disorder program at either the Omaha VA Medical Center or at Catholic Charities Campus for Hope
- diagnosis of methamphetamine dependence as well as presence or history of psychosis based on the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria (not to include patients in full sustained remission)
- provide names, addresses, and phone numbers of at least two collateral informants who can provide information on their methamphetamine and other drug use during follow-up
- must sign an informed consent as approved by the UNMC Internal Review Board (IRB) and Catholic Charities Research Committee.
Exclusion Criteria
- a history of severe injury to their brain
- advanced cardiac, pulmonary, renal or liver disease
- predisposition to seizures
- history of bulimia or anorexia nervosa
- current diagnosis of major depressive disorder
- diagnosis or past history of panic disorders, schizophrenia, or bipolar affective disorder
- family history or childhood history of epilepsy or seizures
- history of strokes, brain tumors, or bleeding in the brain.
- used any psychoactive drug within one week of study entry (two weeks for MAO (monoamine oxidase) inhibitors or protriptyline, four weeks for fluoxetine)
- currently using any theophylline product (e.g. Theodur)
- used an investigational drug in any study within the past four weeks
- used a therapeutic course of bupropion SR for > 1 week at any time in the past 12 months or have been evaluated in previous studies examining bupropion SR at anytime
- If female, the participant must not be pregnant or breast feeding
Data sourced from ClinicalTrials.gov (NCT00572234). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.